Copy to clipboard 
Medacta reported 1H22 orthopedic sales of $215.5 million, +19% compared to the first half of 2021.
Continued salesforce expansion, new customer acquisition and new product introductions drove Medacta’s growth. COVID restrictions and hospital staffing shortages in the U.S. and Australia offset some of the company’s gains, however.
Medacta’s NextAR system reached 1,000 surgeries during its limited release. The hardware requires a limited capital investment and features low-cost single-use instruments, making it ideal for the ASC market in the U.S.
During the first half, the company achieved the milestone of 100 NextAR systems in the market. The May full market release of the shoulder application helped drive adoption. The system expanded its international reach in late June with regulatory approval in Japan.
Given its first-half performance, Medacta expects to achieve the upper end of its $408 million to $422 million guidance range.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $194.7 | $163.8 | $30.9 | 18.9% |
| Knees | $78.8 | $64.7 | $14.1 | 21.8% |
| Hips | $103.4 | $90.1 | $13.3 | 14.7% |
| Extremities | $12.5 | $9.0 | $3.5 | 39.3% |
| Spine | $20.2 | $16.9 | $3.3 | 19.4% |
| Sports Medicine | $0.6 | $0.3 | $0.3 | 85% |
| Total | $215.5 | $181.0 | $34.4 | 19% |
Orthopedic Sales by Geography
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $65.5 | $53.6 | $11.9 | 22.2% |
| OUS | $150.0 | $127.4 | $22.5 | 17.7% |
| EMEA | $96.2 | $77.7 | $18.5 | 23.8% |
| APAC | $45.7 | $43.9 | $1.8 | 4.1% |
| ROW | $8.1 | $5.8 | $2.2 | 38.5% |
| Total | $215.5 | $181.0 | $34.4 | 19% |
Medacta reported 1H22 orthopedic sales of $215.5 million, +19% compared to the first half of 2021.
Continued salesforce expansion, new customer acquisition and new product introductions drove Medacta's growth. COVID restrictions and hospital staffing shortages in the U.S. and Australia offset some of the company's gains, however.
...
Medacta reported 1H22 orthopedic sales of $215.5 million, +19% compared to the first half of 2021.
Continued salesforce expansion, new customer acquisition and new product introductions drove Medacta’s growth. COVID restrictions and hospital staffing shortages in the U.S. and Australia offset some of the company’s gains, however.
Medacta’s NextAR system reached 1,000 surgeries during its limited release. The hardware requires a limited capital investment and features low-cost single-use instruments, making it ideal for the ASC market in the U.S.
During the first half, the company achieved the milestone of 100 NextAR systems in the market. The May full market release of the shoulder application helped drive adoption. The system expanded its international reach in late June with regulatory approval in Japan.
Given its first-half performance, Medacta expects to achieve the upper end of its $408 million to $422 million guidance range.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $194.7 | $163.8 | $30.9 | 18.9% |
| Knees | $78.8 | $64.7 | $14.1 | 21.8% |
| Hips | $103.4 | $90.1 | $13.3 | 14.7% |
| Extremities | $12.5 | $9.0 | $3.5 | 39.3% |
| Spine | $20.2 | $16.9 | $3.3 | 19.4% |
| Sports Medicine | $0.6 | $0.3 | $0.3 | 85% |
| Total | $215.5 | $181.0 | $34.4 | 19% |
Orthopedic Sales by Geography
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $65.5 | $53.6 | $11.9 | 22.2% |
| OUS | $150.0 | $127.4 | $22.5 | 17.7% |
| EMEA | $96.2 | $77.7 | $18.5 | 23.8% |
| APAC | $45.7 | $43.9 | $1.8 | 4.1% |
| ROW | $8.1 | $5.8 | $2.2 | 38.5% |
| Total | $215.5 | $181.0 | $34.4 | 19% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
